NewAmsterdam Pharma N.V. Quarterly Cash Flow Statement
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NewAmsterdam Pharma N.V. free cash flow
In the quarter ended Jun 30, 2026, NewAmsterdam Pharma N.V. generated -$39.2 million of operating cash flow and spent $80,000 on capital expenditures. That left free cash flow of -$39.3 million, a free-cash-flow margin of -1061.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
NewAmsterdam Pharma N.V. cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -64.14M | -48.44M | -74.92M | -72.00M | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M | -93.77M | -49.49M | -47.13M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 59.00K | 62.00K | 59.00K | 64.00K | 45.00K | 52.00K | 51.00K | 28.00K | 19.00K | 15.00K | 13.00K | 14.00K |
| Stock-Based Compensation | 18.38M | 18.00M | 14.02M | 15.01M | 15.18M | 15.21M | 9.41M | 8.00M | 8.29M | 7.92M | 6.01M | 5.39M |
| Change in Working Capital | -2.69M | -793.00K | 9.30M | -2.27M | -3.42M | -727.00K | -1.68M | 119.00K | -5.62M | -9.71M | 12.09M | -12.18M |
| Operating Cash Flow | -39.21M | -30.60M | -40.88M | -32.77M | -37.67M | -36.47M | -37.48M | -12.50M | -53.98M | -54.60M | -33.07M | -46.98M |
| Capital Expenditures | -80.00K | -38.00K | -100.00K | -42.00K | -88.00K | -16.00K | -3.00K | -75.00K | -209.00K | -385.00K | -3.00K | -9.00K |
| Investing Cash Flow | -4.76M | -11.51M | -21.14M | 2.51M | -159.14M | 2.85M | -62.18M | -75.00K | -209.00K | -385.00K | -3.00K | -9.00K |
| Financing Cash Flow | 11.04M | 11.06M | 13.68M | 5.89M | 3.42M | 6.52M | 456.61M | 58.00K | 4.66M | 198.18M | 0 | 186.00K |
| Net Change in Cash | -32.94M | -31.05M | -48.33M | -24.37M | -193.38M | -27.09M | 356.95M | -12.52M | -49.53M | 143.19M | -33.08M | -46.80M |
| Free Cash Flow | -39.29M | -30.64M | -40.98M | -32.81M | -37.76M | -36.48M | -37.48M | -12.58M | -54.19M | -54.99M | -33.08M | -46.98M |
This table shows 12 quarterly periods of NewAmsterdam Pharma N.V.'s cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NAMS's reporting calendar. What is a cash flow statement?